We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
-4.85%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$1.91M
Cap. Flow
+$19.3M
Cap. Flow %
9.17%
Top 10 Hldgs %
63.34%
Holding
39
New
3
Increased
22
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$8.5M
2
LLY icon
Eli Lilly
LLY
+$5.39M
3
BSX icon
Boston Scientific
BSX
+$4.23M
4
RVMD icon
Revolution Medicines
RVMD
+$3.14M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.44M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.39M
2
MRK icon
Merck
MRK
+$5.05M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$3.31M
4
IMCR icon
Immunocore
IMCR
+$1.68M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$1.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JANX icon
26
Janux Therapeutics
JANX
$1.01B
$2.08M 0.99%
+39,573
New +$2.09M
ONC
27
BeOne Medicines Ltd
ONC
$40.6B
$2M 0.95%
+10,900
New +$2.23M
KRYS icon
28
Krystal Biotech
KRYS
$9.68B
$1.47M 0.7%
9,202
– –
MREO
29
Mereo BioPharma
MREO
$48.8M
$1.37M 0.65%
390,000
+190,000
+95% +$746K
SMMT icon
30
Summit Therapeutics
SMMT
$12.1B
$1.31M 0.62%
101,177
+15,164
+18% +$294K
CRBP icon
31
Corbus Pharmaceuticals
CRBP
$184M
$1.19M 0.56%
98,304
+28,731
+41% +$482K
AUTL
32
Autolus Therapeutics
AUTL
$620M
$1.06M 0.5%
479,644
+37,221
+8% +$126K
SLNO
33
DELISTED
Soleno Therapeutics
SLNO
$985K 0.47%
30,940
+4,550
+17% +$236K
MRSN
34
DELISTED
Mersana Therapeutics
MRSN
$765K 0.36%
21,545
– –
PHVS icon
35
Pharvaris
PHVS
$2.41B
$653K 0.31%
34,328
– –
CABA icon
36
Cabaletta Bio
CABA
$455M
$554K 0.26%
247,454
+78,932
+47% +$277K
IMCR icon
37
Immunocore
IMCR
$1.74B
– –
-54,060
Closed -$1.68M
IONS icon
38
Ionis Pharmaceuticals
IONS
$9.21B
– –
-82,691
Closed -$3.31M
REGN icon
39
Regeneron Pharmaceuticals
REGN
$82.1B
– –
-7,028
Closed -$7.39M
1
2

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
OCMH
Oxbow Capital Management (HK) Hong Kong $371M AUM 383.45% 1-Year Est. Return

HealthInvest Partners's Q4 2024 Portfolio in Review

As of Q4 2024, HealthInvest Partners held 39 positions worth $211M, down 0.9% from $213M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

HealthInvest Partners deployed $19.3M of net new capital in Q4 2024, opening 3 new positions and adding to 22 existing holdings. Its largest new stake was Revolution Medicines: 62,161 shares worth $2.68M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Merck, an estimated $5.05M trimmed.

  • HealthInvest Partners's largest Q4 2024 buy was Revolution Medicines: 62,161 shares worth $2.68M.
  • HealthInvest Partners added most to AbbVie in Q4 2024, an estimated $8.5M increase.
  • HealthInvest Partners's biggest Q4 2024 reduction was Merck, cutting an estimated $5.05M.
  • HealthInvest Partners fully exited Regeneron Pharmaceuticals in Q4 2024, selling an estimated $7.39M.
  • HealthInvest Partners's ten largest holdings make up 63% of its $211M portfolio in Q4 2024.
  • HealthInvest Partners opened 3 new positions and closed 3 in Q4 2024.
  • HealthInvest Partners's portfolio value fell 0.9% quarter-over-quarter to $211M.

Based on HealthInvest Partners's 13F filing for Q4 2024, filed 4 Feb 2025.